Scott Durbin

Chief Executive Officer & Director

Mr. Durbin joined Viveve in early 2013 and became Chief Executive Officer and Director in May 2018. He previously served as the Company’s Chief Financial Officer and has been instrumental in the Company’s growth. He is committed to leading the Company and the clinical and commercial development of its innovative CMRF technology to solidify its position as a global leader in women’s intimate health. Mr. Durbin’s 25-year career in the life sciences industry covers corporate finance, strategy, clinical, and operational experience. Prior to joining Viveve, he was chief financial officer of Aastrom Biosciences, Inc., a publicly traded, cardiovascular cell therapy company. In 2004, Mr. Durbin began his six years as chief operating and financial officer for Prescient Medical, Inc. (“PMI”), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to PMI, he spent several years as a financial consultant for two publicly traded biotech companies, Scios, Inc. – a Johnson & Johnson company, and Alteon, Inc. Mr. Durbin began his corporate finance career as an investment banker in the healthcare and M&A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotech companies. Preceding his advance into corporate finance, he served as a Director of Neurophysiology for Biotronic, Inc. Mr. Durbin received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.

Interested in learning more about investing?

Go to Viveve's Investor Site

Product Indications

Viveve System
The Viveve System is indicated for general surgery for electrocoagulation and hemostasis in the United States.
Viveve Solutions
The Viveve System is indicated for general surgery for electrocoagulation and hemostasis in the United States. The InControl Products (InToneMV) is indicated for the treatment of all forms of urinary incontinence in the United States and Canada.